These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 15380336)

  • 1. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
    Wright DG; Boosalis M; Malek K; Waraska K
    Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
    Wright DG; Boosalis MS; Waraska K; Oshry LJ; Weintraub LR; Vosburgh E
    Anticancer Res; 1996; 16(6A):3349-51. PubMed ID: 9042310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
    Malek K; Boosalis MS; Waraska K; Mitchell BS; Wright DG
    Leuk Res; 2004 Nov; 28(11):1125-36. PubMed ID: 15380335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene.
    Gharehbaghi K; Burgess GS; Collart FR; Litz-Jackson S; Huberman E; Jayaram HN; Boswell HS
    Leukemia; 1994 Aug; 8(8):1257-63. PubMed ID: 7520100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of cell differentiation in melanoma cells by inhibitors of IMP dehydrogenase: altered patterns of IMP dehydrogenase expression and activity.
    Kiguchi K; Collart FR; Henning-Chubb C; Huberman E
    Cell Growth Differ; 1990 Jun; 1(6):259-70. PubMed ID: 1980599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot G; Weber G
    Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
    Jayaram HN; O'Connor A; Grant MR; Yang H; Grieco PA; Cooney DA
    J Exp Ther Oncol; 1996 Sep; 1(5):278-85. PubMed ID: 9414415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.
    Jayaram HN; Cooney DA; Grusch M; Krupitza G
    Curr Med Chem; 1999 Jul; 6(7):561-74. PubMed ID: 10390601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells.
    Jayaram HN; Gharehbaghi K; Jayaram NH; Rieser J; Krohn K; Paull KD
    Biochem Biophys Res Commun; 1992 Aug; 186(3):1600-6. PubMed ID: 1354960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells.
    Vitale M; Zamai L; Falcieri E; Zauli G; Gobbi P; Santi S; Cinti C; Weber G
    Cytometry; 1997 Feb; 30(1):61-6. PubMed ID: 9056744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tiazofurin: biological effects and clinical uses.
    Tricot G; Jayaram HN; Weber G; Hoffman R
    Int J Cell Cloning; 1990 May; 8(3):161-70. PubMed ID: 2189014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
    Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents.
    Franchetti P; Grifantini M
    Curr Med Chem; 1999 Jul; 6(7):599-614. PubMed ID: 10390603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective up-regulation of type II inosine 5'-monophosphate dehydrogenase messenger RNA expression in human leukemias.
    Nagai M; Natsumeda Y; Konno Y; Hoffman R; Irino S; Weber G
    Cancer Res; 1991 Aug; 51(15):3886-90. PubMed ID: 1677309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.
    Gharehbaghi K; Sreenath A; Hao Z; Paull KD; Szekeres T; Cooney DA; Krohn K; Jayaram HN
    Biochem Pharmacol; 1994 Oct; 48(7):1413-9. PubMed ID: 7945441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
    Jayaram HN; Zhen W; Gharehbaghi K
    Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis.
    Yalowitz JA; Jayaram HN
    Anticancer Res; 2000; 20(4):2329-38. PubMed ID: 10953293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tiazofurin on globin and proto-oncogene expression in K562 erythroleukemia cells.
    Kharbanda SM; Miyazaki K; Takeyama H; Sherman ML; Spriggs DR; Carney WP; Kufe DW
    Cancer Commun; 1989; 1(3):191-7. PubMed ID: 2639729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine.
    Vethe NT; Bremer S; Bergan S
    Scand J Clin Lab Invest; 2008; 68(4):277-85. PubMed ID: 18609073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.